knowledge -WSS

knowledge

author：explore 2025-10-01 01:50:56 - browse：27234

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Wearables generate powerful data but its not useful to doctors, yet

WSS

Military medical care influenced by rank and race, new study finds

UPS workers' union leader explains what's at stake as strike edges closer

Cytokinetics CEO stresses company can launch heart drug on its own

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Solving academic medical centers' existential crisis

Wikipedia

knowledge

focus

Affirmative action in medical school literally saved lives

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

In Memoriam: Notable people who died in 2023

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Medical leaders decry Supreme Court decision on affirmative action

HIV vaccine remains elusive. Immunologists keep trying new ideas

Medicare details structure of new drug price negotiation program

How corporate America is slashing DEI workers amid backlash to diversity programs

After affirmative action ruling, medical educators look to 'holistic review'

With measles on the rise, a personal story of a devastating disease

focus

The PBM ad wars are taking over Washington, D.C.

Arc Institute generative AI designs new CRISPR systems

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

North Korean leader's powerful sister says warplanes repelled US spy plane

Another man arrested in connection with shooting at Kansas nightclub

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

focus

hotspot

focus

focus